Oncostatin M (OSM) is a type of cytokine, which is a small signaling protein that is involved in regulating various aspects of the immune response and inflammation. OSM belongs to the interleukin-6 (IL-6) family of cytokines and is produced by a variety of cell types, including activated T-cells, monocytes, and macrophages.
OSM binds to a specific receptor, which consists of two subunits, and activates signaling pathways that can influence the growth and differentiation of various cell types, including hematopoietic cells, muscle cells, and neuronal cells. OSM has been shown to play a role in a number of physiological and pathological processes, including inflammation, tissue repair, and cancer.
Oncostatin M (OSM), a member of the IL-6 cytokine family, plays a role in various
homeostatic and pathophysiological processes. OSM promotes tissue repair and
remodeling, but also regulates growth of different cancer cells. Upregulation of OSM
promotes skin and lung inflammation or atherosclerosis [1].
OSM appears to be involved in the maintenance of intestinal inflammation, as OSM
and its receptor OSMR are increasingly expressed in the intestinal mucosa of patients
with inflammatory bowel disease (IBD) and primarily influence the subsequent
inflammatory response [2]. A 2020 study has shown that a combination of OSM with
the established inflammatory marker calprotectin is beneficial for IBD diagnosis [3].
The treatment of IBD (e.g. Crohn’s disease, ulcerative colitis), rheumatic diseases or
psoriasis is increasingly carried out with anti-TNFα antibodies, which directly intervene in the underlying inflammatory reaction. However, this treatment does not
work in about 40% of patients (primary treatment failure) or loses its effect over time
(secondary treatment failure). Diverse studies have shown an association between
elevated OSM concentrations and reduced treatment success with anti-TNFα antibodies [4, 5, 6, 7]. Thus, the amount of OSM in the gut can be used as a predictive
biomarker for primary treatment failure of TNFα inhibitors in IBD.
The IDK® Oncostatin M ELISA can be used to determine the level of OSM in serum,
plasma and stool. The results help the treating physician to plan and optimize
therapy.
https://www.immundiagnostik.com/en/testkits/k-6926
.Theranostica Ltd can supplay ELISA kit for OSM